Share-based Payment Arrangement, Expense of HERON THERAPEUTICS, INC. /DE/ from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
HERON THERAPEUTICS, INC. /DE/ quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • HERON THERAPEUTICS, INC. /DE/ Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $2,179,000, a 5.1% decline year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $10,339,000, a 20% decline year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ annual Share-based Payment Arrangement, Expense for 2025 was $10,339,000, a 20% decline from 2024.
  • HERON THERAPEUTICS, INC. /DE/ annual Share-based Payment Arrangement, Expense for 2024 was $12,962,000, a 61% decline from 2023.
  • HERON THERAPEUTICS, INC. /DE/ annual Share-based Payment Arrangement, Expense for 2023 was $32,854,000, a 24% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

HERON THERAPEUTICS, INC. /DE/ Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,339,000 $2,179,000 -$116,000 -5.1% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $10,455,000 $2,852,000 +$130,000 +4.8% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $10,325,000 $2,797,000 -$1,773,000 -39% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $12,098,000 $2,511,000 -$864,000 -26% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $12,962,000 $2,295,000 -$2,029,000 -47% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $14,991,000 $2,722,000 -$3,961,000 -59% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $18,952,000 $4,570,000 -$9,330,000 -67% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $28,282,000 $3,375,000 -$4,572,000 -58% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $32,854,000 $4,324,000 -$6,190,000 -59% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $39,044,000 $6,683,000 -$4,515,000 -40% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $43,559,000 $13,900,000 +$3,547,000 +34% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $40,012,000 $7,947,000 -$2,968,000 -27% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $42,980,000 $10,514,000 -$2,374,000 -18% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $45,354,000 $11,198,000 -$38,000 -0.34% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $45,392,000 $10,353,000 -$888,000 -7.9% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $46,280,000 $10,915,000 -$571,000 -5% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $46,851,000 $12,888,000 -$3,147,000 -20% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $49,998,000 $11,236,000 +$141,000 +1.3% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $49,857,000 $11,241,000 +$127,000 +1.1% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $49,730,000 $11,486,000 -$488,000 -4.1% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $50,218,000 $16,035,000 +$4,936,000 +44% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $45,282,000 $11,095,000 +$1,391,000 +14% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $43,891,000 $11,114,000 -$1,592,000 -13% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $45,483,000 $11,974,000 -$5,928,000 -33% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $51,411,000 $11,099,000 +$1,304,000 +13% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $50,107,000 $9,704,000 +$1,654,000 +21% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $48,453,000 $12,706,000 +$4,885,000 +62% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $43,568,000 $17,902,000 +$10,201,000 +132% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $33,367,000 $9,795,000 +$2,904,000 +42% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $30,463,000 $8,050,000 +$574,000 +7.7% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $29,889,000 $7,821,000 -$329,000 -4% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2
Q1 2018 $30,218,000 $7,701,000 -$320,000 -4% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $30,538,000 $6,891,000 -$368,000 -5.1% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $30,906,000 $7,476,000 -$35,000 -0.47% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $30,941,000 $8,150,000 +$2,319,000 +40% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $28,622,000 $8,021,000 +$2,666,000 +50% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $25,956,000 $7,259,000 +$1,412,000 +24% 01 Oct 2016 31 Dec 2016 10-K 22 Feb 2019 2018 FY
Q3 2016 $24,544,000 $7,511,000 +$4,690,000 +166% 01 Jul 2016 30 Sep 2016 10-Q 06 Nov 2017 2017 Q3
Q2 2016 $19,854,000 $5,831,000 +$2,690,000 +86% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $17,164,000 $5,355,000 +$2,804,000 +110% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $14,360,000 $5,847,000 +$3,589,000 +159% 01 Oct 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
Q3 2015 $10,771,000 $2,821,000 +$1,061,000 +60% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $9,710,000 $3,141,000 +$2,061,000 +191% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $7,649,000 $2,551,000 -$418,000 -14% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $8,067,000 $2,258,000 -$299,000 -12% 01 Oct 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
Q3 2014 $8,366,000 $1,760,000 -$2,335,000 -57% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $10,701,000 $1,080,000 -$1,323,000 -55% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $12,024,000 $2,969,000 +$1,134,000 +62% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q4 2013 $10,890,000 $2,557,000 +$598,000 +31% 01 Oct 2013 31 Dec 2013 10-K 19 Feb 2016 2015 FY
Q3 2013 $10,292,000 $4,095,000 +$2,115,000 +107% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $8,177,000 $2,403,000 +$1,388,000 +137% 01 Apr 2013 30 Jun 2013 10-Q 04 Aug 2014 2014 Q2
Q1 2013 $6,789,000 $1,835,000 +$1,057,000 +136% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q4 2012 $5,732,000 $1,959,000 01 Oct 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
Q3 2012 $1,980,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $1,015,000 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013 2013 Q2
Q1 2012 $778,000 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1

HERON THERAPEUTICS, INC. /DE/ Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $10,339,000 -$2,623,000 -20% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $12,962,000 -$19,892,000 -61% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $32,854,000 -$10,126,000 -24% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $42,980,000 -$3,871,000 -8.3% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $46,851,000 -$3,367,000 -6.7% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $50,218,000 -$1,193,000 -2.3% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022 2021 FY
2019 $51,411,000 +$18,044,000 +54% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $33,367,000 +$2,829,000 +9.3% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $30,538,000 +$4,582,000 +18% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $25,956,000 +$11,596,000 +81% 01 Jan 2016 31 Dec 2016 10-K 22 Feb 2019 2018 FY
2015 $14,360,000 +$6,293,000 +78% 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
2014 $8,067,000 -$2,823,000 -26% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $10,890,000 +$5,158,000 +90% 01 Jan 2013 31 Dec 2013 10-K 19 Feb 2016 2015 FY
2012 $5,732,000 +$3,842,000 +203% 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
2011 $1,890,000 01 Jan 2011 31 Dec 2011 10-K 07 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.